C4 Therapeutics Inc.
CCCC | NASDAQ
$3.38
+$0.08 (+2.42%)
Sep 22, 2026, 10:51 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | 35.95M | 35.58M | 20.76M | 31.1M | 45.79M | 33.2M |
Cost of Revenue | 7.98M | n/a | 7.74M | n/a | n/a | 78.44M |
Gross Profit | 27.97M | 35.58M | 13.02M | 31.1M | 45.79M | -45.25M |
Operating Income | -104.49M | -119.61M | -139.03M | -129.53M | -82.13M | -60.45M |
Interest Income | 10.35M | 14.43M | 9.81M | 3.58M | 387K | 393K |
Pretax Income | -104.87M | -105.19M | -131.21M | -128.18M | -83.89M | -65.71M |
Net Income | -104.99M | -105.32M | -132.49M | -128.18M | -83.89M | -66.33M |
Selling & General & Admin | 36.2M | 42.12M | 42.08M | 42.79M | 33.25M | 15.2M |
Research & Development | 104.24M | 110.64M | 117.71M | 117.84M | 94.67M | 78.44M |
Other Expenses | -7.98M | 2.44M | -7.74M | n/a | n/a | -78.44M |
Operating Expenses | 132.46M | 155.2M | 152.05M | 160.63M | 127.92M | 15.2M |
Interest Expense | n/a | n/a | 1.37M | 2.22M | 2.15M | 1.23M |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 140.44M | 155.2M | 159.79M | 160.63M | 127.92M | 93.64M |
Income Tax Expense | 121K | 131K | 1.28M | n/a | n/a | 626K |
Shares Outstanding (Basic) | 82.89M | 69.37M | 49.64M | 48.86M | 46.04M | 43.06M |
Shares Outstanding (Diluted) | 82.89M | 69.37M | 49.64M | 48.86M | 46.04M | 43.06M |
EPS (Basic) | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | -1.54 |
EPS (Diluted) | -1.27 | -1.52 | -2.67 | -2.62 | -1.82 | -1.54 |
EBITDA | -102.91M | -103.37M | -122.1M | -124.28M | -80.26M | -58.83M |
EBIT | -104.87M | -105.19M | -129.84M | -125.96M | -81.75M | -60.45M |
Depreciation & Amortization | 1.96M | 1.82M | 7.74M | 1.68M | 1.49M | 1.62M |
Add to Watchlist
Select watchlists to add or remove CCCC